# US 2004/0018170 A1 · Immune modulation with death receptor-induced apoptosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018170 A1
- Document ID: US20040018170A1
- Status: Published application
- Kind: A1
- Application number: 10/202,613
- Filed: 2002-07-23
- Published: 2004-01-29
- Earliest claimed: 2002-07-23
- Assignees: University of Louisville Research Foundation, Inc.
- Inventors: Haval Shirwan
- Web page: https://patentgrep.com/patent/US20040018170A1

## CPC

- C07K 14/525: Tumour necrosis factor [TNF]
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeric protein, the selected cell undergoes apoptosis. The preferred embodiment is FasL protein fused to streptavidin. The methods of using the chimeric proteins are especially beneficial in causing activated lymphocytes to undergo apoptosis, thus modulating the immune response. Patients with conditions such as asthma or allergy, or patients undergoing transplantation with allogeneic or xenogeneic tissue are examples of patients who benefit from the methods of this invention.

## Claims

### Claim 1

A chimeric protein comprising an apoptosis-inducing protein fused to a member of a binding pair that is capable of binding to a selected cell expressing a death receptor.

### Claim 2 (depends on 1)

The chimeric protein of claim 1 wherein the apoptosis-inducing protein is FasL, mFasL, TNFα, TWEAK or TRAIL and the binding pair is capable of causing the said chimeric protein to form tetramers.

### Claim 3 (depends on 2)

The chimeric protein of claim 2 in which the member of the said binding pair is streptavidin or avidin.

### Claim 4 (depends on 1)

The chimeric protein of claim 1 wherein the apoptosis-inducing protein is FasL, mFasL, TNFα, TWEAK or TRAIL and the member of a binding pair is an antibody or fragment thereof that specifically binds said selected cell expressing a death receptor.

### Claim 5 (depends on 1)

The chimeric protein of claim 1 wherein the said selected cell expressing a death receptor is an activated lymphocyte.

### Claim 6 (depends on 1)

A method for inducing apoptosis in selected cells expressing death receptors comprising
exposing said cells to an effective amount of the chimeric protein of claim 1.

### Claim 7 (depends on 6)

The method of claim 6 wherein said selected cells expressing a death receptor are activated lymphocytes.

### Claim 8 (depends on 1, 6)

The method of claim 6 wherein said selected cells are exposed in vivo to an effective amount of the chimeric protein of claim 1.

### Claim 9 (depends on 1, 6)

The method of claim 6 wherein said selected cells are exposed ex vivo toan effective amount of the chimeric protein of claim 1.

### Claim 10 (depends on 5)

A method of inducing immune modulation in a mammal comprising the administration of an effective amount of the chimeric protein of claim 5 to a mammal having a condition which is alleviated by the apoptosis of activated lymphocytes.

### Claim 11 (depends on 9)

The method of claim 9 wherein the said condition is asthma, allergy, food poisoning, autoimmunity or transplantation of an allogeneic or xenogeneic tissue.

### Claim 12 (depends on 10)

The method of claim 10 wherein the autoimmune condition is diabetes, multiple sclerosis, lupus erythematosis, sarcoidosis or rheumatoid arthritis.

### Claim 13 (depends on 1)

An effector cell comprising a biotinylated cell decorated with the chimeric protein of claim 1.

### Claim 14 (depends on 9, 13)

The method of claim 9 wherein the selected cells are exposed to the effector cells of claim 13.

### Claim 15 (depends on 1)

A substrate comprising a biotinylated solid matrix fused to the chimeric protein of claim 1.

### Claim 16 (depends on 15)

The substrate of claim 15 wherein the said solid matrix is an agarose bead.

### Claim 17 (depends on 16)

A method of inducing immune tolerance in a mammal comprising:
(a) the removal of lymphocytes from said mammal;
(b) exposing said lymphocytes to the substrate of claim 16; and
(c) returning said lymphocytes to said mammal.

### Claim 18

A chimeric protein comprising an apoptosis-inducing protein fused to a member of a binding pair that is capable of binding to a selected cell expressing a death receptor.

### Claim 19 (depends on 18)

The chimeric protein of claim 18 wherein the apoptosis-inducing protein is FasL, mFasL, TNFα, TWEAK or TRAIL and the binding pair is capable of causing the chimeric protein to form tetramers.

### Claim 20 (depends on 18, 19)

The chimeric protein of claim 18 or 19 in which the member of the binding pair is streptavidin or avidin.

### Claim 21 (depends on 18, 19, 20)

The chimeric protein of any of claims 18, 19 or 20 wherein the apoptosis-inducing protein is FasL, mFasL, TNFα, TWEAK or TRAIL and the member of the binding pair is an antibody or fragment thereof that specifically binds the selected cell expressing a death receptor.

### Claim 22 (depends on 18, 19, 20, 21)

The chimeric protein of any of claims 18, 19, 20 or 21 wherein the selected cell expressing a death receptor is an activated lymphocyte.

### Claim 23 (depends on 18, 19, 20, 21, 22)

A method for inducing apoptosis in a selected cell expressing a death receptor comprising exposing the cell to an effective amount of the chimeric protein of any of claims 18 through 22.

### Claim 24 (depends on 23)

The method of claim 23 wherein the selected cell expressing a death receptor is an activated lymphocyte.

### Claim 25 (depends on 1, 2, 3, 4, 5, 23, 24)

The method of claim 23 or 24 wherein the selected cell is exposed in vivo to an effective amount of the chimeric protein of any of claims 1 through 5.

### Claim 26 (depends on 18, 19, 20, 21, 22, 23, 24)

The method of claim 23 or 24 wherein the selected cell is exposed ex vivo to an effective amount of the chimeric protein of any of claims 18 through 22.

### Claim 27 (depends on 22)

A method of inducing immune modulation in a mammal comprising the administration of an effective amount of the chimeric protein of claim 22 to a mammal having a condition which is alleviated by the apoptosis of activated lymphocytes.

### Claim 28 (depends on 27)

The method of claim 27 wherein the condition is asthma, allergy, food poisoning, autoimmunity or transplantation of an allogeneic or xenogeneic cell, organ or tissue graft.

### Claim 29 (depends on 27)

The method of claim 27 wherein the condition is diabetes, multiple sclerosis, lupus erythematosis, sarcoidosis or rheumatoid arthritis.

### Claim 30 (depends on 18, 19, 20, 21, 22)

An effector cell comprising a biotinylated cell decorated with the chimeric protein of any of claims 18 through 22.

### Claim 31 (depends on 26, 30)

The method of claim 26 wherein the selected cell is exposed to the effector cell of claim 30.

### Claim 32 (depends on 18, 19, 20, 21, 22)

A substrate comprising a biotinylated solid matrix fused to the chimeric protein of any of claims 18 through 22.

### Claim 33 (depends on 32)

The substrate of claim 32 wherein the solid matrix is an agarose bead.

### Claim 34 (depends on 33)

A method of inducing immune tolerance in a mammal comprising:
(a) removing a lymphocyte from the mammal;
(b) exposing the lymphocyte to the substrate of claim 33; and
(c) returning the lymphocyte to the mammal.

### Claim 35 (depends on 18, 19, 20, 21, 22)

The chimeric protein of any of claims 18 through 22, wherein the apoptosis-inducing protein binds to the selected cell expressing a death receptor.

### Claim 36 (depends on 18, 19, 20, 21, 22)

The chimeric protein of any of claims 18 through 22, wherein the member of the binding pair binds to the selected cell expressing a death receptor.

### Claim 37 (depends on 18)

The chimeric protein of claim 18 wherein the apoptosis-inducing protein is FasL, mFasL, TNFα, TWEAK or TRAIL and wherein the chimeric protein forms tetramers.

### Claim 38 (depends on 18, 19, 20, 21, 22)

A method for inducing apoptosis in a selected cell expressing a death receptor comprising contacting the cell with an effective amount of the chimeric protein of any of claims 18 through 22.

### Claim 39 (depends on 18, 19, 20, 21, 22, 23)

The method of claim 23 wherein the selected cell is contacted in vivo with an effective amount of the chimeric protein of any of claims 18 through 22.

### Claim 40 (depends on 18, 19, 20, 21, 22, 23)

The method of claim 23 wherein the selected cell is contacted ex vivo with an effective amount of the chimeric protein of any of claims 18 through 22.

### Claim 41 (depends on 33)

A method of inducing immune tolerance in a mammal comprising:
(a) removing a lymphocyte from the mammal;
(b) contacting the lymphocyte with the substrate of claim 33; and
(c) placing the lymphocyte in or on the mammal.
